Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA

DarioHealth Reports Third Quarter 2018 Results


NEW YORK and CAESAREA, Israel, Nov. 13, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today reported financial and operational results for the third quarter ended September 30, 2018.

"We are excited to report that in the third quarter of 2018 we increased revenues by 37% compared to the third quarter of 2017, and in addition we have recorded an additional $335,000 in deferred revenues. This quarter represents a shift of our business from selling devices and disposables, into our digital health membership offering which provides higher margins. The deferred revenues are driven by our recently launched annual membership plan," stated Erez Raphael, CEO of DarioHealth.

"During the third quarter, we continued growing all key parameters of the business including total number of patients on the platform, average revenue per patient per month (ARPU), number of CDEs (certified diabetes educators) on the platform, while also launching our one-year memberships program," Mr. Raphael continued.

"We are particularly excited to report continued growth in our recurring revenues, with over 50% of our third quarter revenues in the U.S. being recurring. This increase in recurring revenues is an important part of our business model, as we expect it will improve predictability as we move forward," concluded Mr. Raphael.

Olivier Jarry, President and Chief Commercial Officer of DarioHealth stated, "During the third quarter, DarioHealth has led negotiations with major business-to-business accounts in the U.S. and Canada including retail chains, clinic networks, and distributors. These are expected to translate into signed agreements and revenues in the fourth quarter. As a result of these efforts, we signed our largest product rollout agreement through a U.S. retailer to date with Giant Eagle. Millions Giant Eagle customers, through 214 in-store pharmacy locations will be able to sign up for online education and rewards through the DarioHealth Blood Glucose Monitoring System and smartphone application."

Recent Operational Highlights

Dario Health (PRNewsfoto/DarioHealth Corp.)

Financial Highlights

Third Quarter 2018 Results Summary

Revenue for the third quarter ended September 30, 2018 was $1.88 million, a 37% increase from $1.37 million in the third quarter ended September 30, 2017.

Revenue for the third quarter of 2018 included direct-to-consumer sales in the United States and Australia, as well as sales in Germany, and product sales to distributors in the United Kingdom and Canada. We recorded an additional $335,000 as deferred revenues from revenues generated from our new membership offering to our customers in the U.S.

Gross profit increased by $192,000, a 70% increase, to a gross profit of $468,000 in the third quarter of 2018, as compared to a gross profit of $276,000 in the third quarter of 2017.

Operating loss for the third quarter ended September 30, 2018 increased by $952,000 to $3.93 million, as compared to a $2.98 million operating loss in the third quarter ended September 30, 2017. This increase was mainly due to an increase in our sales and marketing expenses.

Net loss attributable to holders of common stock increased by $1.1 million to $4.06 million in the third quarter of 2018, as compared to $2.97 million in the third quarter of 2017.

As of September 30, 2018, cash and cash equivalents totaled $11.4 million.

Financial Results for the Nine Months Ended September 30, 2018:

Revenue for the nine months ended September 30, 2018 was $5.7 million, a 58% increase from $3.6 million for the nine months ended September 30, 2017. We recorded an additional $385,000 as deferred revenues from revenues generated from our new membership offering to our customers in the U.S.

Gross profit of $1.54 million was recorded for the nine months ended September 30, 2018, an increase of 108%, or $800,000, compared to a gross profit of $742,000 for the nine months ended September 30, 2017.

Operating loss for the nine months ended September 30, 2018 increased by $1.2 million to $12.5 million, compared to a $11.3 million operating loss for the nine months ended September 30, 2017.

Net loss was $12.8 million for the nine months ended September 30, 2018 compared to a net loss of $12.5 million for the nine months ended September 30, 2017. The increase in net loss for the nine months ended September 30, 2018 compared to the nine months ended September 30, 2017 was mainly due to the increase in our operating expenses partially offset by the increase in our gross profit, and the reduction in our financing expenses related to revaluation of warrants.

Conference Call Details:

Date: Tuesday, November 13, 2018
Time: 9:00am ET
Dial-in Number: 1-877-407-8035
International Dial-in Number: 1-201-689-8035
Webcast: http://www.investorcalendar.com/event/40657

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when the Company describes expected improvements in recurring revenues, when it describes expected signed agreements and revenues in the fourth quarter of 2018, and when it describes potential market opportunities.  Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dariotm as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

DARIOHEALTH CORP.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands




September 30,



December 31,




2018



2017




Unaudited





ASSETS


















CURRENT ASSETS:









Cash and cash equivalents


$

11,427



$

3,718


Short-term bank deposits



184




258


Trade Receivables



374




282


Inventories



1,020




1,184


Other accounts receivable and prepaid expenses



523




604











Total current assets



13,528




6,046











LEASE DEPOSITS



47




42











PROPERTY AND EQUIPMENT, NET



758




869











Total assets


$

14,333



$

6,957


 

DARIOHEALTH CORP.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except stock and stock data)





September 30,



December 31,



2018



2017




Unaudited












LIABILITIES AND STOCKHOLDERS' EQUITY


















CURRENT LIABILITIES:









Trade payables


$

2,203



$

1,852


Deferred revenues



385




-


Other accounts payable and accrued expenses



1,334




1,163











Total current liabilities



3,922




3,015











LIABILITY RELATED TO WARRANTS



-




1











STOCKHOLDERS' EQUITY









Common Stock of $0.0001 par value -
Authorized: 160,000,000 shares at September 30, 2018
(unaudited) and December 31, 2017; Issued and Outstanding:
25,691,724 and 14,074,238 shares at September 30, 2018
(unaudited) and December 31, 2017, respectively



7




7


Preferred Stock of $0.0001 par value -
Authorized: 5,000,000 shares at September 30, 2018
(
unaudited) and December 31, 2017; Issued and Outstanding:
1,890,257 and 0 shares at September 30, 2018 (unaudited)
and December 31, 2017, respectively



*)-




-


Additional paid-in capital



94,675




74,892


Accumulated deficit



(84,271)




(70,958)











Total stockholders' equity



10,411




3,941











Total liabilities and stockholders' equity


$

14,333



$

6,957


 

*) Represents an amount lower than $1.

 

DARIOHEALTH CORP.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except stock and stock data)




Three months ended

September 30



Nine months ended

September 30




2018



2017



2018



2017




Unaudited



Unaudited















Revenues


$

1,879



$

1,375



$

5,694



$

3,592


Cost of revenues



1,411




1,099




4,152




2,850



















Gross profit



468




276




1,542




742



















Operating expenses:

















Research and development


$

997



$

797



$

2,749



$

2,450


Sales and marketing



2,693




1,677




6,820




5,707


General and administrative



709




781




4,506




3,887



















Total operating expenses



4,399




3,255




14,075




12,044



















Operating loss



(3,931)




(2,979)




(12,533)




(11,302)



















Financial income (expenses), net:

















Revaluation of warrants




*)-



1




1




(1,169)


Other financial (expense) income, net



(132)




5




(288)




(7)



















Total financial income (expenses), net



(132)




6




(287)




(1,176)



















Net loss


$

(4,063)



$

(2,973)



$

(12,820)



$

(12,478)



















Deemed dividend related to warrant exchange agreement


$

-



$

-



$

493



$

-


Net loss attributable to holders of Common Stock


$

(4,063)



$

(2,973)



$

(13,313)



$

(12,478)



















Net loss per share


































Basic and diluted loss per share


$

(0.17)



$

(0.30)



$

(0.67)



$

(1.40)


Weighted average number of Common Stock
used in computing basic and diluted net loss
per share



23,533,328




9,950,443




19,733,291




8,931,460


 

*) Represents an amount lower than $1.

 

DARIOHEALTH CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands




Nine months ended

September 30,




2018



2017




Unaudited









Cash flows from operating activities:









Net loss


$

(12,820)



$

(12,478)


Adjustments required to reconcile net loss to net cash used in operating activities:









Stock-based compensation and Common Stock to service providers



3,284




3,062


Depreciation



160




155


Increase in trade receivables



(92)




(193)


Decrease (increase) in accounts receivables and prepaid expenses



81




(264)


Decrease (increase) in inventories



164




(36)


Increase in trade payables



351




171


Increase in other accounts payable and accrued expenses



457




191


Increase in deferred revenues



385




-


Change in fair value of warrants to purchase shares of Common Stock



(1)




1,169











Net cash used in operating activities



(8,031)




(8,223)











Cash flows from investing activities:









Maturity (investment) of (in) short-term bank deposits



74




(16)


Maturity (investment) in lease deposits



(5)




3


Purchase of property and equipment



(49)




(64)











Net cash provided by (used in) investing activities



20




(77)











Cash flows from financing activities:









Proceeds from issuance of Common Stock and warrants, net of issuance cost



15,720




13,469


Proceeds from exercise of options and warrants



-




(*-











Net cash provided by financing activities



15,720




13,469











Increase in cash and cash equivalents



7,709




5,169


Cash and cash equivalents at the beginning of the period



3,718




1,093











Cash and cash equivalents at the end of the period


$

11,427



$

6,262











Non-cash investing and financing activities:









Reclassification of warrants from liability to equity


$

-



$

8,655


Payment for directors, employees and service providers under Stock for Cash Program


$

286



$

183


 

*) Represents an amount lower than $1.

 

DarioHealth Corporate Contact: Joao Mendes-Roter, VP Marketing, [email protected], 1-347-767-4220

SOURCE DarioHealth Corp.


These press releases may also interest you

at 13:24
Susan G. Komen®, the world's leading breast cancer organization, applauds Representative Patty Acomb (D-Minnetonka) for introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the...

at 13:16
Risas Dental & Braces ("Risas"), a dental and braces provider that serves patients in Arizona, Colorado, Texas, and Nevada, has learned of a data security incident that may have involved the protected health information of certain Risas patients....

at 13:15
The "Long-Acting Drug Delivery Technologies and Services Market: A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering. As of 2022, the global long-acting drug delivery technologies and services...

at 13:15
The "Global Organoids And Spheroids Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global organoids and spheroids market size was estimated to be USD 0.781 billion in 2023 and is anticipated...

at 13:05
Regulatory News: MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today reported...

at 13:00
The following is written by Dr. Steven Gonzales, Chancellor, Maricopa Community Colleges, a member of the American Association of Community Colleges: Arizona, like many states across America, is facing a nurse shortage.  The pandemic has taken a toll...



News published on and distributed by: